News | Radiopharmaceuticals and Tracers | September 11, 2015

Westinghouse Signs Memorandum of Understanding with NorthStar to Produce Medical Radioisotopes

Partnership will work together to address global production capacity shortage of molybdenum-99

September 11, 2015 — Westinghouse Electric Company and NorthStar Medical Radioisotopes announced a memorandum of understanding to explore producing medical radioisotopes from the core of commercial nuclear reactors, and methods of global distribution. The exploration involves generating the most widely used radioisotope in medical diagnostic imaging by treating an isotope of the chemical element molybdenum rather than enriched uranium.

The effort is to address a global production capacity shortage of the medical radioisotope molybdenum-99 (Mo-99), as well as a nuclear proliferation concern with current methods, which rely on enriched uranium as source material. Both societal needs will be answered by using the highly reliable, high-volume production capacity of commercial nuclear reactors to make Mo-99 by irradiating molybdenum-98, and would require little capital investment by nuclear plant operators.

“Nuclear plants operate at very high capacity factors, and there are plants around the world that have the capability to produce Mo-99,” said Cindy Pezze, vice president and chief technology officer, Westinghouse. “Not only does commercial nuclear power provide reliable electricity without greenhouse gases, it can additionally contribute to society by making important diagnostic isotopes available globally.”

Westinghouse has a patent pending for producing medical radioisotopes using the existing Westinghouse plant design Incore Instrumentation System. NorthStar has been developing a process for using enriched Mo-98 targets as the starting point for Mo-99 rather than enriched uranium.

For more information: www.westinghousenuclear.com

Related Content

Bracco Imaging Acquires Blue Earth Diagnostics
News | Radiopharmaceuticals and Tracers | July 01, 2019
Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company...
DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
United Imaging Announces First U.S. Clinical Install of uMI 550 Digital PET/CT System
News | PET-CT | June 19, 2019
United Imaging announced the first U.S. clinical installation of the uMI 550 Digital positron emission tomography/...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse

Figure 1. A high-fidelity 3-D tractography of the left ventricle heart muscle fibers of a mouse from Amsterdam Ph.D. researcher Gustav Strijkers.

News | Magnetic Resonance Imaging (MRI) | June 07, 2019
The Amsterdam University Medical Center has won MR Solutions’ Image of the Year 2019 award for the best molecular...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
Study Explores Magnetic Nanoparticles as Bimodal Imaging Agent for PET/MRI

Image courtesy of MR Solutions.

News | PET-MRI | May 23, 2019
Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...